Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesBrain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications
Current Drug Targets, 10/30/09
Dremencov E et al. – The observations suggest that the intensification of norepinephrine transmission can be beneficial in the treatment of affective disorders. However, various psychotropic medications have indirect effect on norepinephrine transmission. This review examines the effects of psychiatric medications on the norepinephrine system and proposes how they might be used to improve treatment outcome.
Related Articles
Glutamate-based antidepressants: 20 years on
Trends in Pharmacological Sciences, 10/29/09
Relevance Score: 66%
The Role of Sodium Channels in the Mechanism of Action of Antidepressants and Mood Stabilizers
Current Drug Targets, 10/30/09
Relevance Score: 64%
Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes
Journal of Pharmacology and Experimental Therapeutics, 10/26/09
Relevance Score: 64%
Early induction of CREB activation and CREB-regulating signalling by antidepressants
International Journal of Neuropsychopharmacology, 10/21/09
Relevance Score: 64%
Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression
Expert Opinion on Investigational Drugs, 10/02/09
Relevance Score: 64%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Propylene Glycol Accumulation in Critically Ill Patients Receiving Continuous Intravenous Lorazepam Infusions
Annals of Pharmacotherapy, 11/25/09
Effect of cilnidipine vs losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: a randomized controlled trial
Acta Neurologica Scandinavica, 11/25/09
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Sponsor
Article Search
Sponsor